Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

$22.49

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Analysis of Solvency Ratios
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Solvency Ratios (Summary)

Biogen Inc., solvency ratios (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Debt Ratios
Debt to equity
Debt to equity (including operating lease liability)
Debt to capital
Debt to capital (including operating lease liability)
Debt to assets
Debt to assets (including operating lease liability)
Financial leverage

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).


Debt to Equity
The debt to equity ratio exhibits a general declining trend from 0.57 in March 2017 to 0.42 by March 2018, indicating reduced reliance on debt relative to equity during this period. Following this, there is a period of relative stability fluctuating between 0.43 and 0.48 until early 2020. Starting from March 2020, the ratio increases notably to a peak near 0.7 by late 2021, suggesting an increased leverage position, before declining again to 0.49 by September 2022.
Debt to Equity (Including Operating Lease Liability)
This metric parallels the trend observed in the standard debt to equity ratio but generally presents slightly higher values. It starts at 0.57 in March 2017, decreases to approximately 0.42 by March 2018, and follows a stable pattern until early 2020. Afterward, there is a marked increase to about 0.73 in late 2020 and 2021, before decreasing to 0.52 by September 2022. The inclusion of operating lease liabilities slightly elevates the leverage metrics throughout.
Debt to Capital
The debt to capital ratio trends downward from 0.36 in early 2017 to 0.3 by March 2018, matching the initial improvement in capital structure. It remains generally stable near 0.3–0.31 through 2019, then increases sharply from early 2020 to about 0.41 by late 2020 and 2021, suggesting a higher proportion of debt in the total capital structure. By late 2022, the ratio decreases back toward 0.33, indicating some deleveraging.
Debt to Capital (Including Operating Lease Liability)
This ratio closely mirrors the debt to capital ratio but maintains slightly elevated figures due to the inclusion of operating lease liabilities. The trend shows an initial decrease to 0.3 by early 2018, stability through 2019, a notable increase to approximately 0.42 during 2020 and 2021, followed by a decline to 0.34 by the third quarter of 2022.
Debt to Assets
The debt to assets ratio declines from 0.31 in early 2017 to 0.23 by March 2018, indicating a stronger asset base relative to debt. The ratio remains fairly consistent around 0.22 to 0.23 during 2019 and early 2020, then increases to approximately 0.3 during 2020 and 2021, reflecting elevated debt levels or reduced asset base in this period. The ratio decreases again to 0.25 in late 2022.
Debt to Assets (Including Operating Lease Liability)
This measure is similar to the standard debt to assets ratio but is slightly higher due to accounting for operating lease liabilities. The trend follows the same general pattern: a decrease to around 0.23 by early 2018, stability through 2019, an increase to about 0.32 in 2020 and 2021, then a reduction to 0.27 by September 2022.
Financial Leverage
Financial leverage, indicating the degree to which assets are financed by equity, fluctuates moderately between 1.79 and 1.95 during 2017 and 2018. It rises consistently from early 2019 onward, reaching a peak around 2.32 in late 2020, signifying increased use of debt or other liabilities to finance assets. Post-2020, there is a gradual decline to approximately 1.95 by the third quarter of 2022, pointing to a modest reduction in leverage.

Debt Ratios


Debt to Equity

Biogen Inc., debt to equity calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Current portion of notes payable
Notes payable, excluding current portion
Total debt
 
Total Biogen Inc. shareholders’ equity
Solvency Ratio
Debt to equity1
Benchmarks
Debt to Equity, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
Debt to equity = Total debt ÷ Total Biogen Inc. shareholders’ equity
= ÷ =

2 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals several notable trends regarding total debt, shareholders’ equity, and the debt to equity ratio over the observed periods.

Total Debt
Total debt remained relatively stable during 2017 and 2018, fluctuating slightly around 5.9 to 6.5 billion US dollars. During 2019 and early 2020, debt levels continued near 5.9 to 7.4 billion, but a significant increase is observed in mid-2020 where total debt rose sharply to approximately 7.4 billion US dollars, maintaining around that level through 2021. Toward the last observed quarter in September 2022, total debt decreased markedly to approximately 6.28 billion US dollars, indicating a reduction of nearly 1.4 billion from previous peaks.
Shareholders’ Equity
Shareholders’ equity showed moderate growth during most of 2017 and 2018, rising from about 11.5 billion to roughly 14 billion US dollars, though with some volatility quarter-to-quarter. Through 2019 and into early 2020, equity declined steadily from around 14 billion to approximately 10.7 billion US dollars by the end of 2020. From 2021 onwards, equity gradually recovered, rising from near 10.7 billion to an estimated 12.8 billion by the third quarter of 2022.
Debt to Equity Ratio
The debt to equity ratio trended downward from 0.57 in early 2017 to a low of approximately 0.42 in early 2018, reflecting either decreasing debt relative to equity or rising equity relative to debt. Between 2018 and early 2020, the ratio fluctuated moderately between 0.43 and 0.48. A marked increase occurred in mid-2020, peaking near 0.69, coinciding with the noted surge in total debt and decline in equity. In 2021, the ratio remained elevated around 0.67 to 0.70. However, by mid to late 2022, the ratio declined significantly to 0.49, aligning with the reduction in total debt and recovery in equity values.

In summary, the company experienced stable debt and gradually growing equity early in the observed period, followed by a period of increased leverage and equity decline in 2020. The subsequent quarters indicate deleveraging efforts and equity recovery, resulting in improved capital structure metrics by late 2022.


Debt to Equity (including Operating Lease Liability)

Biogen Inc., debt to equity (including operating lease liability) calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Current portion of notes payable
Notes payable, excluding current portion
Total debt
Long-term operating lease liabilities
Total debt (including operating lease liability)
 
Total Biogen Inc. shareholders’ equity
Solvency Ratio
Debt to equity (including operating lease liability)1
Benchmarks
Debt to Equity (including Operating Lease Liability), Competitors2
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Total Biogen Inc. shareholders’ equity
= ÷ =

2 Click competitor name to see calculations.


The financial data exhibits notable trends in debt levels, shareholders’ equity, and the debt-to-equity ratio over the analyzed periods.

Total Debt (including operating lease liability)
The total debt remained relatively stable between March 2017 and December 2019, fluctuating slightly around the 6,500,000 to 6,300,000 thousand US$ range. A sharp increase occurred starting from June 2020, peaking near 7,838,600 thousand US$ by this period. After that, total debt gradually declined to 6,634,000 thousand US$ by September 2022. This pattern suggests a phase of increased borrowing or lease obligations around mid-2020, followed by a strategy to reduce overall debt levels through 2021 and 2022.
Total Shareholders' Equity
Shareholders’ equity demonstrated volatility with an overall upward trajectory from March 2017 through September 2022. Initial values were around 11,479,000 thousand US$ in early 2017, with pronounced fluctuations observed throughout 2018 and 2019, reaching peaks above 13,800,000 thousand US$. Subsequently, there was a decline through mid-2020 to lower values near 10,700,000 thousand US$, indicating possible impacts from external or internal challenges during this period. From late 2020 onward, equity showed recovery and steady growth, closing at approximately 12,775,500 thousand US$ by September 2022.
Debt to Equity Ratio (including operating lease liability)
The debt-to-equity ratio declined from 0.57 in early 2017 to a low of approximately 0.42 by the first quarter of 2018, indicating improved leverage and potentially stronger equity positions relative to debt. However, from mid-2019, the ratio increased significantly, reaching highs of 0.73 between mid-2020 and late 2021. This elevation in leverage corresponds with the noted surge in debt and the decrease in equity during the same timeframe. Subsequently, the ratio began to decline steadily from early 2022, dropping to 0.52 by the third quarter of 2022, aligning with reductions in debt and improvements in equity.

Overall, the data reflects a period of increased financial leverage and debt accumulation around 2020, accompanied by a dip in equity, potentially indicative of strategic financing decisions or external pressures. Following this period, the company appears to have taken steps to deleverage and strengthen equity, contributing to a reduction in the debt-to-equity ratio as of late 2021 and into 2022.


Debt to Capital

Biogen Inc., debt to capital calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Current portion of notes payable
Notes payable, excluding current portion
Total debt
Total Biogen Inc. shareholders’ equity
Total capital
Solvency Ratio
Debt to capital1
Benchmarks
Debt to Capital, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =

2 Click competitor name to see calculations.


Total Debt
The total debt exhibited relative stability from March 2017 through March 2020, maintaining a range roughly between 5,932 million and 6,514 million USD. Starting in June 2020, there was a marked increase in total debt levels, peaking near 7,426 million USD in December 2020. Following this peak, total debt remained fairly consistent around the 7,270 million USD range throughout 2021 and the first half of 2022. By September 2022, there was a significant decline in total debt to approximately 6,279 million USD.
Total Capital
Total capital fluctuated over the periods observed. From March 2017 to December 2019, total capital varied, peaking near 19,972 million USD in September 2019 before declining slightly. In early 2020, total capital demonstrated a gradual decline, particularly evident from March 2020 through December 2020, dropping from around 18,509 million USD to approximately 18,126 million USD. During 2021, total capital remained relatively stable within the 17,700 to 18,000 million USD range but showed some recovery in mid-2022, reaching nearly 19,150 million USD by September 2022.
Debt to Capital Ratio
The debt to capital ratio generally trended downward from 0.36 in the early months of 2017 to a low of approximately 0.30 in early 2018, indicating a decreased reliance on debt relative to capital. This ratio remained fairly stable around the 0.30 to 0.32 range throughout 2018 and 2019. Beginning mid-2020, the ratio increased sharply, reaching a high of about 0.41 toward the end of 2020 and maintaining at this elevated level throughout most of 2021. The ratio began to decline gradually in 2022, falling to approximately 0.33 by September 2022, which corresponds with the decrease in total debt and moderate recovery in total capital observed.

Debt to Capital (including Operating Lease Liability)

Biogen Inc., debt to capital (including operating lease liability) calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Current portion of notes payable
Notes payable, excluding current portion
Total debt
Long-term operating lease liabilities
Total debt (including operating lease liability)
Total Biogen Inc. shareholders’ equity
Total capital (including operating lease liability)
Solvency Ratio
Debt to capital (including operating lease liability)1
Benchmarks
Debt to Capital (including Operating Lease Liability), Competitors2
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= ÷ =

2 Click competitor name to see calculations.


Total Debt (Including Operating Lease Liability)
The total debt remained relatively stable from March 2017 through December 2019, fluctuating around 6.3 to 6.5 billion US dollars. However, starting in the first quarter of 2020, there was a noticeable increase, peaking near 7.8 billion US dollars in the first three quarters of 2020. Following that peak, the total debt gradually declined through 2021 and 2022, reaching approximately 6.6 billion US dollars by September 2022. This indicates a period of increased leverage in early 2020, followed by a deleveraging trend over the subsequent two years.
Total Capital (Including Operating Lease Liability)
Total capital displayed moderate fluctuations throughout the time frame. Between 2017 and 2018, capital levels ranged approximately from 18.0 billion to 20.3 billion US dollars, with some variability across quarters. There was a decline in capital in 2019, with values around 19.3 to 20.3 billion, followed by a downward trend in 2020, bottoming out near 18.5 billion US dollars by December 2020. From 2021 onward, total capital showed a gradual upward trend, reaching just over 19.4 billion US dollars by September 2022. Overall, total capital experienced periods of both decline and recovery but remained relatively stable within a band of approximately 18 to 20 billion US dollars.
Debt to Capital Ratio (Including Operating Lease Liability)
The debt to capital ratio demonstrated a general downward trend from 0.36 in early 2017 to a low of around 0.30 in early 2018, suggesting a reduction in leverage relative to capital during that period. Subsequently, the ratio hovered between 0.30 and 0.34 until the end of 2019. Beginning in early 2020, a pronounced increase in the leverage ratio occurred, peaking around 0.42 through most of 2020 and 2021. This reflects a period where debt grew faster than capital, increasing financial leverage. Toward the end of the observed period, in mid to late 2022, the ratio fell from approximately 0.40 to 0.34, indicating a decrease in leverage and an improved capital structure.

Debt to Assets

Biogen Inc., debt to assets calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Current portion of notes payable
Notes payable, excluding current portion
Total debt
 
Total assets
Solvency Ratio
Debt to assets1
Benchmarks
Debt to Assets, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =

2 Click competitor name to see calculations.


The financial data over the analyzed periods reveals several key trends in the company's debt structure and asset base.

Total Debt

Total debt remained fairly stable from March 2017 through March 2020, fluctuating just slightly around the 5.9 to 6.5 billion US dollars range. However, starting in June 2020, there was a notable increase in total debt, rising sharply to approximately 7.4 billion US dollars where it remained relatively constant through March 2022. Towards the final observed period, in September 2022, total debt decreased significantly to around 6.3 billion US dollars.

Total Assets

Total assets showed an overall growth trend from March 2017 through December 2019, increasing from roughly 21.2 billion to about 27.2 billion US dollars. This upward trend reversed from March 2020 onward, with assets declining consistently to a low near 23.6 billion by March 2022. In the last period recorded, September 2022, there was a modest recovery to approximately 24.8 billion US dollars.

Debt to Assets Ratio

The debt to assets ratio declined steadily from 0.31 in March 2017 to a low near 0.22 in late 2019, indicative of improving leverage and financial stability relative to asset base expansion. This trend reversed beginning in March 2020, with the ratio increasing sharply to about 0.30 by mid-2020 and maintaining that higher level through late 2021. A decrease to 0.25 is evident in the final period observed, coinciding with the reduction in total debt and slight asset recovery.

Overall, the company experienced a period of asset growth accompanied by reduced leverage through late 2019. From 2020 onward, a contrasting pattern emerges with increasing debt levels and decreasing total assets resulting in elevated leverage ratios. The recent data from mid to late 2022 suggests a strategic deleveraging effort and partial asset base stabilization. These shifts may reflect responses to external market conditions or internal financing decisions during the examined timeframe.


Debt to Assets (including Operating Lease Liability)

Biogen Inc., debt to assets (including operating lease liability) calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Current portion of notes payable
Notes payable, excluding current portion
Total debt
Long-term operating lease liabilities
Total debt (including operating lease liability)
 
Total assets
Solvency Ratio
Debt to assets (including operating lease liability)1
Benchmarks
Debt to Assets (including Operating Lease Liability), Competitors2
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= ÷ =

2 Click competitor name to see calculations.


The financial data reveals notable trends in the company's debt and asset management over the observed quarters. Total debt, including operating lease liability, exhibited relative stability during the initial periods, remaining around the 6.5 billion US dollar mark from March 2017 through December 2017. A gradual increase is observable starting March 2019, with a sharp rise between March 2020 and June 2020 where debt climbs from approximately 6.37 billion to 7.84 billion US dollars. Following this peak, total debt shows a declining trend towards the last reported quarter in September 2022, reducing to approximately 6.63 billion US dollars.

Total assets display an overall increasing trend from March 2017 through September 2019, growing from about 21.2 billion to roughly 27.5 billion US dollars. However, a reversal occurs post-2019, with assets consistently decreasing to approximately 24.7 billion by December 2020. In 2021, asset levels fluctuate but remain relatively stable around the 23.8 to 24.5 billion range. The final quarters indicate a recovery trend, as assets increase again to near 24.9 billion US dollars by September 2022.

The debt-to-assets ratio, which measures leverage, reflects the interplay between debt and asset values. Initially, the ratio decreases from 0.31 in March 2017 to a low of 0.23 around December 2017 and remains near that level with minor fluctuations until early 2020. From March 2020 onwards, the ratio increases sharply to 0.31–0.32 range indicating higher leverage concomitant with the surge in debt and decline in assets during the same period. Entering 2022, this ratio begins to improve, falling to 0.27 by September 2022, aligning with the reduction in debt and asset value recovery.

Overall, the data indicates a period of debt consolidation and asset growth until late 2019, followed by a phase of increased leverage due to rising debt and declining assets during 2020 and early 2021. The subsequent quarters suggest strategic efforts toward deleveraging and asset base stabilization, improving the company’s financial structure as reflected by the declining debt-to-assets ratio in the most recent periods.


Financial Leverage

Biogen Inc., financial leverage calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Total assets
Total Biogen Inc. shareholders’ equity
Solvency Ratio
Financial leverage1
Benchmarks
Financial Leverage, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
Financial leverage = Total assets ÷ Total Biogen Inc. shareholders’ equity
= ÷ =

2 Click competitor name to see calculations.


Total Assets
The total assets demonstrated an overall increasing trend from March 31, 2017, to September 30, 2019, rising from approximately $21.2 billion to $27.5 billion. Following this peak, total assets gradually declined through December 31, 2020, reaching around $24.6 billion. Subsequently, asset values fluctuated with a slight downward trend until the first quarter of 2022, before showing moderate growth again by mid-2022, closing near $24.9 billion. This pattern suggests initial asset growth followed by consolidation and moderate recovery.
Total Biogen Inc. Shareholders’ Equity
Shareholders' equity broadly increased during the early period, peaking at approximately $14.1 billion in March 2018, then experienced a steady decline until December 2020, reaching about $10.7 billion. In the quarters after this low point, equity remained relatively stable with minor fluctuations, before demonstrating a notable recovery starting in the second quarter of 2021, culminating in an increase to roughly $12.8 billion by September 2022. This trend indicates a period of equity reduction followed by stabilization and recovery.
Financial Leverage
The financial leverage ratio exhibited moderate variability over the period. Initially ranging between 1.79 and 1.95 from 2017 through early 2019, it increased to peak values above 2.3 in mid-2020, suggesting a higher reliance on debt during that period. Post-peak, leverage showed a gradual decline, reducing to approximately 1.95 by the third quarter of 2022. This trend highlights a period of increased leverage corresponding to declining equity, followed by efforts to reduce leverage toward the latter period.
Summary Insights
The financial data reveals a phase of asset growth paired with increasing shareholders' equity until early 2018, followed by a contraction in equity and elevated financial leverage, indicating potential financial strain or strategic changes involving increased debt usage. The latter part of the timeline shows efforts to stabilize and improve the equity position and reduce leverage, implying a focus on strengthening the balance sheet and possibly improving financial stability. The fluctuations in total assets alongside these changes emphasize a dynamic period with shifts in financial structure and capital management strategies.